Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
8
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
8
×
san francisco top stories
seattle blog main
seattle top stories
startups
8
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
biotech
boston top stories
deals
cancer
alzheimer's disease
biogen
cancer immunotherapy
eli lilly
gilead sciences
abbvie
fda
ipo
medicare
What
bio
8
×
roundup
drug
acquisitions
ceo
new
alzheimer’s
biggest
companies
covid
daniel
gilead
ipo
medicines
o’day
pharmaceutical
price
sciences
typically
activity
albert
announced
approval
approvals
bails
biogen
biogen’s
biopharmaceutical
bourla
brand
bridgebio
build
buy
capital
car
clamped
collabs
company
company’s
congress
Language
unset
unknown
Current search:
bio
×
" san francisco blog main "
×
startups
×
novartis
×
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Midterm Fallout, Alzheimer’s Search, Postpartum Panel